title: Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia.
authors.affiliation: Department of Internal Medicine III, Hematology & Oncology, University Hospital of Regensburg, Regensburg simone.thomas@ukr.de.
authors.forename: Simone
authors.initials: S
authors.lastname: Thomas
authors.affiliation: Department of Internal Medicine III, Hematology & Oncology, University Hospital of Regensburg, Regensburg.
authors.forename: Roland
authors.initials: R
authors.lastname: Schelker
authors.affiliation: Department of Internal Medicine III, Hematology & Oncology, University Hospital of Regensburg, Regensburg.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Klobuch
authors.affiliation: Department of Internal Medicine III, Hematology & Oncology, University Hospital of Regensburg, Regensburg.
authors.forename: Sascha
authors.initials: S
authors.lastname: Zaiss
authors.affiliation: Department of Internal Medicine III, Hematology & Oncology, University Hospital of Regensburg, Regensburg.
authors.forename: Martina
authors.initials: M
authors.lastname: Troppmann
authors.affiliation: Department of Internal Medicine III, Hematology & Oncology, University Hospital of Regensburg, Regensburg.
authors.forename: Michael
authors.initials: M
authors.lastname: Rehli
authors.affiliation: MLL Munich Leukemia Laboratory, Munich, Germany.
authors.forename: Torsten
authors.initials: T
authors.lastname: Haferlach
authors.affiliation: Department of Internal Medicine III, Hematology & Oncology, University Hospital of Regensburg, Regensburg.
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Herr
authors.affiliation: Department of Internal Medicine III, Hematology & Oncology, University Hospital of Regensburg, Regensburg.
authors.forename: Albrecht
authors.initials: A
authors.lastname: Reichle
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001374:Azacitidine / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D000077205:Pioglitazone; D011379:Prognosis; D012074:Remission Induction; D016879:Salvage Therapy; D015996:Survival Rate; D045162:Thiazolidinediones / Q000627:therapeutic use*; D014212:Tretinoin / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D014212:Tretinoin; D001374:Azacitidine; D000077205:Pioglitazone
keywords: 5-azacytidine; ATRA; acute myeloid leukemia; biomodulatory therapy; pioglitazone